Search Results

You are looking at 81 - 90 of 420 items for :

  • "single agent" x
Clear All
Full access

of single-agent tivozanib in patients with platinum-resistant ovarian cancer Contacts: Mario Pineda, MD, PhD • 312-472-4684 Wendy Swetzig • 312-472-5727 • wendy.swetzig@northwestern.edu Jamie Sherr • 312-472-5757 • jamie

Full access

of the efficacy of single-agent enzalutamide, based on overall response rate, in subjects with relapsed/refractory MCL or previously untreated MCL Secondary Objectives: Evaluate the duration of disease control (progression-free survival) in

Full access

lead-in (Part A), 6 patients will be treated with the combination of enzalutamide, standard intravenous carboplatin, and paclitaxel. Patients on the phase II portion of study (Part B) will undergo induction treatment with single-agent enzalutamide at

Full access

of the efficacy of single-agent enzalutamide, based on overall response rate, in subjects with relapsed/refractory MCL Secondary Objectives: Evaluate the duration of disease control (progression-free survival) in patients with MCL treated

Full access

addition, agents with antiangiogenic properties have shown single-agent activity in this disease. Sorafenib has been shown to have a 14% response rate in angiosarcomas in previously treated patients in the phase II setting. Bevacizumab has demonstrated a 12

Full access

characterize the safety of single-agent tivozanib in patients with platinum-resistant ovarian cancer Contacts: Mario Pineda, MD, PhD • 312-472-4684 Rachel Bers, BS • 312-472-5726 • r-bers@northwestern.edu Doreine Carson, MS • 312 472-4681 • d

Full access

twice daily or the dose used in previous sorafenib-based therapy, until they experience unacceptable toxicity or disease progression, after which sorafenib can be continued as a single agent. Primary Objective: Determine overall survival (OS) at 6

Full access

antiangiogenic agent. In addition, agents with antiangiogenic properties have shown single-agent activity in this disease. Sorafenib has been shown to have a 14% response rate in angiosarcomas in previously treated patients in the phase II setting. Bevacizumab

Full access

-resistant, recurrent ovarian, fallopian tube, or primary peritoneal cancer (referred to collectively as ovarian cancer ) Secondary Objective: Determine the potential survival advantage and characterize the safety of single-agent tivozanib in patients with

Full access

David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN and Miranda Hughes

-Line Immunotherapy Regimens Pembrolizumab Monotherapy Clinical Trial Data A phase III randomized trial (KEYNOTE-024) compared single-agent pembrolizumab versus platinum-based chemotherapy as first-line therapy for patients with advanced squamous cell carcinoma or